Gene Expression Profiles of Metabolic Aggressiveness and Tumor Recurrence in Benign Meningioma

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Serna, Eva ^a   Morales, José Manuel ^a   Mata, Manuel ^a   Gonzalez Darder, José ^b   San Miguel, Teresa ^a   Gil Benso, Rosario ^a   Lopez Gines, Concha ^a   Cerda Nicolas, Miguel ^a,c   Monleon, Daniel ^b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDE; SOMATOMEDIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CELL INVASION; CONTROLLED STUDY; EARLY DIAGNOSIS; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENINGIOMA; MICROARRAY ANALYSIS; NUCLEAR MAGNETIC RESONANCE; TUMOR RECURRENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIM DOMAIN PROTEINS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; MOLECULAR SEQUENCE ANNOTATION; NEOPLASM RECURRENCE, LOCAL; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84879516171     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067291     Document Type: Article

References (37)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
2. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC, (1999) "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85: 2046-2056.
3. Dumanski JP, Rouleau GA, Nordenskjold M, Collins VP, (1990) Molecular genetic analysis of chromosome 22 in 81 cases of meningioma. Cancer Res 50: 5863-5867.
4. Pfisterer WK, Hank NC, Preul MC, Hendricks WP, Pueschel J, et al. (2004) Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas. Neuro Oncol 6: 290-299.
5. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Callaghan R, Collado M, et al. (2004) Association of loss of 1p and alterations of chromosome 14 in meningioma progression. Cancer Genet Cytogenet 148: 123-128.
6. Perry A, Gutmann DH, Reifenberger G, (2004) Molecular pathogenesis of meningiomas. J Neurooncol 70: 183-202.
7. Pfisterer WK, Coons SW, Aboul-Enein F, Hendricks WP, Scheck AC, et al. (2008) Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. J Neurooncol 87: 43-50.
8. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
9. Monleon D, Morales JM, Gonzalez-Segura A, Gonzalez-Darder JM, Gil-Benso R, et al. (2010) Metabolic Aggressiveness in Benign Meningiomas with Chromosomal Instabilities. Cancer Research 70: 8426-8434.
10. Aarhus M, Lund-Johansen M, Knappskog PM, (2011) Gene expression profiling of meningiomas: current status after a decade of microarray-based transcriptomic studies. Acta Neurochir (Wien) 153: 447-456.
11. Aarhus M, Bruland O, Saetran HA, Mork SJ, Lund-Johansen M, et al. (2010) Global gene expression profiling and tissue microarray reveal novel candidate genes and down-regulation of the tumor suppressor gene CAV1 in sporadic vestibular schwannomas. Neurosurgery 67: 998-1019; discussion 1019.
12. Stuart JE, Lusis EA, Scheck AC, Coons SW, Lal A, et al. (2010) Identification of Gene Markers Associated With Aggressive Meningioma by Filtering Across Multiple Sets of Gene Expression Arrays. J Neuropathol Exp Neurol.
13. Perez-Magan E, Campos-Martin Y, Mur P, Fiano C, Ribalta T, et al. (2012) Genetic alterations associated with progression and recurrence in meningiomas. J Neuropathol Exp Neurol 71: 882-893.
14. Mitelman F, editor (2009) ISCN 1995: an international system for human cytogenetic nomenclature. Basel, Switzerland: Karger Publishers, Inc.
15. Ambros PF, Ambros IM, (2001) Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37: 492-504.
16. Pfisterer WK, Hendricks WP, Scheck AC, Nieman RA, Birkner TH, et al. (2007) Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas? Neurosurgery 61: 1048-1059; discussion 1060-1041.
17. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
18. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
19. Winer J, Jung CK, Shackel I, Williams PM, (1999) Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270: 41-49.
20. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314.
21. Green TR, Fellman JH, Eicher AL, Pratt KL, (1991) Antioxidant role and subcellular location of hypotaurine and taurine in human neutrophils. Biochim Biophys Acta 1073: 91-97.
22. Leon R, Wu H, Jin Y, Wei J, Buddhala C, et al. (2009) Protective function of taurine in glutamate-induced apoptosis in cultured neurons. J Neurosci Res 87: 1185-1194.
23. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
24. Pollak M, (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
25. Sandberg-Nordqvist AC, Stahlbom PA, Reinecke M, Collins VP, von Holst H, et al. (1993) Characterization of insulin-like growth factor 1 in human primary brain tumors. Cancer Res 53: 2475-2478.
26. Collins IM, Beddy P, O'Byrne KJ, (2010) Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor. Acta Oncol 49: 872-874.
27. Valentinis B, Baserga R, (2001) IGF-I receptor signalling in transformation and differentiation. Mol Pathol 54: 133-137.
28. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, et al. (2005) Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 114: 249-256.
29. Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, et al. (2008) Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A 105: 15605-15610.
30. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, et al. (2002) Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709-720.
31. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, et al. (2004) The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 32: D258-261.
32. Ragel BT, Jensen RL, (2010) Aberrant signaling pathways in meningiomas. J Neurooncol 99: 315-324.
33. Aoyama M, Ozaki T, Inuzuka H, Tomotsune D, Hirato J, et al. (2005) LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma. Cancer Res 65: 4587-4597.
34. Larsen S, Yokochi T, Isogai E, Nakamura Y, Ozaki T, et al. (2010) LMO3 interacts with p53 and inhibits its transcriptional activity. Biochem Biophys Res Commun 392: 252-257.
35. Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, et al. (2011) Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 469: 216-220.
36. Lasorella A, Uo T, Iavarone A, (2001) Id proteins at the cross-road of development and cancer. Oncogene 20: 8326-8333.
37. Itahana Y, Singh J, Sumida T, Coppe JP, Parrinello S, et al. (2003) Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells. Cancer Res 63: 7098-7105.